Johnson and Johnson 2010 Annual Report Download - page 9

Download and view the complete annual report

Please find page 9 of the 2010 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

JOHNSON & JOHNSON 2010 ANNUAL REPORT 7
COMMITTED TO RESEARCH With a
passion for scientific research, Ramon
Polo (left) and Brian Woodfall are working
to develop telaprevir for hepatitis C.
Like others at Tibotec in Belgium, they’re
driven by the knowledge that their efforts
have the potential to not only improve
health but help people survive.
discovered. Now in clinical trials, the
treatment, TMC207, will initially target
the increasing number of patients who
have failed tuberculosis therapies due to
drug resistance. Tibotec has partnered
with the nonprofit Global Alliance for
Tuberculosis Drug Development, which
will conduct studies of TMC207 in
patients undergoing TB treatment for
the first time.
In addition, a new HIV drug, TMC278
(rilpivirine), is undergoing regulatory
review and may add to the already strong
HIV portfolio. “It is generally safe and
well-tolerated in clinical trials,” says
Dr. Stoffels. “We hope to create a
life-saving drug with TMC278.”
The two new hepatitis C medicines,
which are protease inhibitors, are also
breakthrough treatments that may offer
new hope to patients who have failed prior
drug therapies. As well, they are intended
for patients being treated for hepatitis C
for the first time. The drugs would be
administered in combination with the
existing standard treatment.
“Our goal is to use our science and
understanding of infectious diseases to
help people survive, improve their health
and make a significant difference in the lives
of patients around the world,”
Dr. Stoffels says. “That is the highest thing
you can do in a human lifetime. This
passion for making a difference in the lives
of patients around the world is what
drives us.”